Skip to main content

Table 1 Patient characteristics

From: Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

Characteristics

Number

Total

25 (100.0%)

Age (years, median)

73.7 (range 29.6–88.2)

ECOG performance status

 0

1 (4.0%)

 1

19 (76.0%)

 2

4 (16.0%)

 3

1 (4.0%)

FIGO stage (2018)

 I

1 (4.0%)

 II

10 (40.0%)

 III

9 (36.0%)

 IV

5 (20.0%)

Pathology

 Squamous cell carcinoma

20 (80.0%)

 Adenocarcnoma

3 (12.0%)

 Poorly differentiated carcinoma

2 (8.0%)

Pelvic organ invasion

 Yes

4 (16.0%)

 No

21 (84.0%)

Pelvic lymph node metastasis

 Yes

9 (36.0%)

 No

16 (64.0%)

Paraaortic lymph node metastasis

 Yes

6 (24.0%)

 No

19 (76.0%)

Distant metastasis

 Yes

2 (8.0%)

 No

23 (92.0%)

Concurrent chemotherapy

 Yes

17 (68.0%)

 No

8 (32.0%)

Consolidation chemotherapy

 Yes

4 (16.0%)

 No

21 (84.0%)

  1. ECOG, eastern cooperative oncology group; FIGO, International Federation of Gynecology and Obstetrics